What is the objective response rate of first-line treatment with osimertinib?

In patients with EGFR mutant non-small cell lung cancer, osimertinib plus chemotherapy resulted in better post-progression survival outcomes compared with osimertinib alone.

After disease progression, the combination of platinum-pemetrexed chemotherapy and osimertinib showed clinically meaningful and statistically significant long-term survival outcomes in patients with non-small cell lung cancer. The combination therapy demonstrated promising results in patients with first-line advanced non-small cell lung cancer, based on a prespecified post-progression analysis and updated survival data from the Phase 3 FLAURA2 trial (NCT04035486).

Study results show that compared with osimertinib alone, patients who received osimertinib plus chemotherapy had a 27% lower risk after their first subsequent treatment After their second progression The risk was reduced by 30% (HR, 0.73; 95%The confidence interval is 0.56-0.94, HR is 0.70; 95%confidence intervals are 0.52-0.93) respectively. The median time to second progression in the combination group (PFS2) was 30.6 months (95% CI, 29.0-Not Calculable[NC]), while the drug alone group was 27.8 months(95% CI, 26.0-NC).

In terms of other post-progression outcomes, the combination treatment improved progression-free survival(PFS) and time to second follow-up treatment(TSST)Corresponding benefits were also observed in terms of , first-term overall survival(OS) and second-term OS, respectively, with HRs of 0.62 (95% CI, 0.49-0.79), 0.69 (95% CI, 0.51-0.93) , 0.90 (95% CI, 0.65-1.24) and 0.75 (95% CI, 0.57-0.75).

The second interim OS analysis of the FLAURA2 trial showed that at a median follow-up of 31.7 months (Range0.1-43.3), the median OS of the combination was not reached(95% CI, 38.0-NC). After median follow-up of 30.5 months(Range:0.1-43.0;P= .0280), the overall maturity of these data is 41%. The probability of overall survival was initially higher with monotherapy at 12 months; however, at 24 and 36 months, the combination benefit was greater.